Navigation Links
Venaxis' APPY1 Test Passes Futility Analysis in Pivotal Clinical Study
Date:7/15/2013

atements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for the APPY1Test required for FDA submission, obtain FDA clearance or approval, maintain CE Marking, cost effectively manufacture and generate revenues from the APPY1Test at a profitable price point, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, Venaxis does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in Venaxis' recent filings with the SEC, including its Prospectus filed on May 24, 2013.

For Investors and Media:
Tiberend Strategic Advisors, Inc.
Joshua Drumm, PhD
jdrumm@tiberend.com; (212) 375-2664
Clair
'/>"/>

SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Venaxis Announces Pricing of Offering of Common Stock and Warrants
2. Venaxis Executes First Commercial Development Agreement and Receives Purchase Order from EMELCA Bioscience for Initial EU Launch
3. YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group
4. Eastern Clinical Trials Russia CRO Passes EMA Inspection
5. Legendary Author And Screenwriter Nora Ephron Passes Away At 71; Solar Cigarette Pays Tribute To Such A Rare Talent
6. Butamax Early Adopters Group surpasses capacity targets with addition of Big River; Membership represents 11 production facilities and nearly 900 million gallons of ethanol capacity
7. Free Expo-Hall Passes for ATA 2012
8. Accuray Surpasses 600 Installations Globally
9. Unisense FertiliTech to Present Large Scale Time-lapse Data Analysis to Improve IVF Treatment
10. New Approaches in Immunogenicity Assessment Using the New SQiDlite™ System: Case Study Analysis, New Life Science Webinar Hosted by Xtalks
11. Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... The new , Healthcare and Life ... today on PharmaBoardroom.com for free download , ... the Spanish economy in 2009, and the austerity measures that ... pragmatic in times of trouble. "Despite the crisis, ... European market, and the general conditions to invest are favorable ...
(Date:9/18/2014)... 18, 2014 A novel robotic system ... scanner is currently being tested as part of a ... in Boston with the aim of determining if the ... prostate cancer biopsies faster, more accurate, less costly, and ... has the potential to deliver prostate cancer therapies with ...
(Date:9/18/2014)... 18, 2014 Research and Markets ... Chinese Stem Cell Industry Report, 2014-2017" report to ... biological cells that can differentiate into specialized cells and ... Stem cell therapy can be applied to treatment of ... nervous system diseases, damage or lesion of liver, kidney ...
(Date:9/18/2014)... LOUIS , Sept. 18, 2014  U.S. biotech ... by signing an exclusive license for technology developed by ... control gene expression in plants, including for applications in ... The technology was developed under the ... officer at Kultevat and former president of the Danforth ...
Breaking Biology Technology:PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Kultevat obtains license of gene switch technology 2
... suffering from uterine fibroids, a debilitating condition that affects ... soon have reason for hope.  Halt Medical, a biomedical ... developing a minimally invasive procedure for treating the condition. ... Latin America at the NIH Global Fibroid Congress.   ...
... One of the requirements to keep trends in computer technology ... energy-efficient is faster writing and processing of data. In ... physicists at the Technische Universitaet Muenchen (TUM) and the Universitaet ... a solution. TUM physicists set a lattice of magnetic vortices ...
... 17, 2010 InterMune, Inc. (Nasdaq: ITMN ... to prepare for the commercialization of Esbriet™ (pirfenidone) in ... a positive CHMP opinion that is now awaiting ratification ... Chief Executive Officer and President of InterMune, said, "We ...
Cached Biology Technology:Halt Medical Presents Strong Results of International Fibroid Studies at National Institutes of Health Global Congress 2Electric current moves magnetic vortices 2InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 2InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 3InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 4InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 5InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 6
(Date:9/18/2014)... BUFFALO, N.Y. A sleep-promoting circuit located deep in ... deep sleep. Discovered by researchers at Harvard School of ... and Biomedical Sciences, this is only the second "sleep ... to be both necessary and sufficient to produce deep ... Neuroscience , the study demonstrates that fully half of ...
(Date:9/18/2014)... robotic system that can operate inside the bore of ... of a biomedical research partnership program at Brigham and ... if the robot, in conjunction with real-time MRI images, ... costly, and less discomforting for the patient. The novel ... therapies with greater precision. , Developed by a team ...
(Date:9/18/2014)... MADISON, Wis. No matter how many times ... as social, communicating creatures. , But by ... single-celled organisms radically alter their behavior to suit ... many of them are present, and act accordingly. ... the millions, it may change from innocuous to ...
Breaking Biology News(10 mins):No sedative necessary: Scientists discover new 'sleep node' in the brain 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3
... that BioMed Central's Open Access journals are high quality ... Central have again received impact factors that compare well ... five titles in the top five of their specialty. ... they are respected by researchers, and are fast becoming ...
... Impressive impact factors prove that BioMed Central's Open Access ... Journals published by BioMed Central have again received impact ... was announced today, with five titles in the top ... these journals affirm that they are respected by researchers, ...
... in repairing lung damage, according to a team of scientists ... repair process in lung transplant patients. , Reporting in today's ... of The University of Texas Medical School at Houston, and ... that less than 1 percent of a certain type of ...
Cached Biology News:'Bionic' arm gives amputee sense of touch 2Open Access journals get impressive impact factors 2Circulating stem cells play small role in lung repair 2Circulating stem cells play small role in lung repair 3
... raised against a partial recombinant ... ZFHX4 (NP_078997, 2 a.a. ... protein with GST tag. ... NM_024721 Protein ...
EPA II Buffer is a diluent formulated to stabilize the activity of Chemicon horseradish peroxidase (HRP)-antibody conjugates at high conjugate dilution for extended periods....
... can design custom microarrays to detect alternative ... Proprietary algorithms are used to identify ... high quality, spliced cDNAs aligned to the ... a custom SpliceArray is profiled with a ...
... DNA Visualizer DX's sensitivity of DNA detection ... DNA band in an agarose gel can be ... this kit can be purified by organic solvent ... tested commercially kits worked well.) DNA excised ...
Biology Products: